NCT04516564View on ClinicalTrials.gov

A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

September 28, 2020

Primary Completion Date

May 4, 2021

Study Completion Date

June 21, 2021

Conditions
Coronavirus Disease 2019 (COVID-19)
Interventions
DRUG

AK119

Single dose of AK119 is administered via intravenous infusion to healthy subjects

DRUG

Placebo

Single dose of placebo is administered via intravenous infusion to healthy subjects

Trial Locations (1)

Unknown

Christchurch Clinical Studies Trust, Christchurch

All Listed Sponsors
lead

Akesobio Australia Pty Ltd

INDUSTRY

NCT04516564 - A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects | Biotech Hunter | Biotech Hunter